Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Sell

Wall Street Data Solutions Rating

Neutral

B

Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)

Pharmaceutical Preparations

http://www.madrigalpharma.com

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

200 BARR HARBOR DRIVE, SUITE 400
WEST CONSHOHOCKEN, PA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/06/2007

Market Cap

5,394,954,569

Shares Outstanding

19,740,000

Weighted SO

19,742,646

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

ICPT --.--%

TGTX --.--%

TERN --.--%

HEPA --.--%

VKTX --.--%

SRPT --.--%

PTCT --.--%

DAWN --.--%

XFOR --.--%

Beta

-0.4260

Last Div

0.0000

Range

119.76-299.98

Chg

3.9700

Avg Vol

421619

Mkt Cap

5394954569

Exch

NASDAQ

Country

US

Phone

267 824 2827

DCF Diff

250.7746

DCF

-0.9246

Div Yield

0.0000

P/S

350.1398

EV Multiple

-9.4645

P/FV

6.2044

Div Yield %

0.0000

P/E

-10.4182

PEG

0.7222

Payout

0.0000

Current Ratio

8.7225

Quick Ratio

8.6660

Cash Ratio

3.9916

DSO

163.4304

DIO

1914.8961

Op Cycle

2078.3265

DPO

2435.3190

CCC

-356.9925

Gross Margin

0.9125

Op Margin

-34.4161

Pretax Margin

-33.1286

Net Margin

-33.1286

Eff Tax Rate

0.0001

ROA

-0.4641

ROE

-0.9561

ROCE

-0.5441

NI/EBT

1.0000

EBT/EBIT

0.9626

EBIT/Rev

-34.4161

Debt Ratio

0.1065

D/E

0.1367

LT Debt/Cap

0.1198

Total Debt/Cap

0.1203

Int Coverage

-817.0786

CF/Debt

-3.8319

Equity Multi

1.2831

Rec Turnover

2.2334

Pay Turnover

0.1499

Inv Turnover

0.1906

FA Turnover

4.8899

Asset Turnover

0.0140

OCF/Share

-20.9766

FCF/Share

-21.2973

Cash/Share

49.6571

OCF/Sales

-29.1378

FCF/OCF

1.0153

CF Coverage

-3.8319

ST Coverage

-806.0233

CapEx Coverage

-65.4167

Div&CapEx Cov

-65.4167

P/BV

6.2044

P/B

6.2044

P/S

350.1398

P/E

-10.4182

P/FCF

-11.8358

P/OCF

-11.8451

P/CF

-11.8451

PEG

0.7222

P/S

350.1398

EV Multiple

-9.4645

P/FV

6.2044

DPS

0.0000

Latest Headlines (EST)

The Motley Fool Feb 02, 23:21 This Stock Just Doubled in 1 Day -- Is It Still a Buy? The Motley Fool Nov 10, 14:30 1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More The Motley Fool Jun 30, 16:02 Is Madrigal Pharmaceuticals a Millionaire Maker? The Motley Fool Jun 16, 16:05 Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word. The Motley Fool Jan 22, 01:29 2 Stocks That Could Soar This Year: Are They Buys? The Motley Fool Jan 22, 01:29 2 Stocks That Could Soar This Year: Are They Buys? Benzinga Jan 12, 14:41 Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development GlobeNewswire Inc. Jan 03, 16:30 Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference The Motley Fool Dec 30, 06:50 3 Stocks That Could Be Monster Winners in 2024 The Motley Fool Dec 30, 06:50 3 Stocks That Could Be Monster Winners in 2024 GlobeNewswire Inc. Dec 22, 16:30 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Dec 22, 16:30 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) The Motley Fool Dec 07, 08:45 These 2 Stocks Could Be About to Soar: Are They Buys? The Motley Fool Nov 30, 05:50 Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money GlobeNewswire Inc. Nov 27, 16:30 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Nov 27, 16:30 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Nov 15, 16:45 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Nov 15, 16:45 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Benzinga Nov 13, 11:00 Analyst Ratings for Madrigal Pharmaceuticals GlobeNewswire Inc. Nov 10, 07:30 Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

Revenue Product Segmentation